biostudies-literatureYin JScience and Technology Bureau of KaifengScience and Technology Department of Henan Province2119763https://www.ebi.ac.uk/biostudies/studies/S-EPMC9746490biostudies-literatureUnknown18(6)Patients with solid cancer have an increased risk of severe coronavirus disease 2019 (COVID-19) and associated mortality than the general population. This meta-analysis aimed to investigate the currently available evidence about the efficacy of COVID-19 vaccines in patients with solid cancer. We included prospective studies comparing the immunogenicity and efficacy of COVID-19 vaccines between patients with solid cancer and healthy individuals. Relative risks of seroconversion after the first and second dose of a COVID-19 vaccine were separately pooled with the use of random effects meta-analysis. Thirty studies with 11,245 subjects met the inclusion criteria. After first vaccine dose, the pooled RR of seroconversion in patients with solid cancer <i>vs</i> healthy individuals was 0.54 (95% CI 0.38-0.78, <i>I</i>^<i>2</i> = 94%). After a second dose, the pooled RR of seroconversion in patients with solid cancer <i>vs</i> healthy controls was 0.87 (0.86-0.88, <i>I</i>^<i>2</i> = 87%). Our review suggests that, compared with healthy individuals, COVID-19 vaccines show favorable immunogenicity and efficacy in patients with solid cancer. A second dose is associated with significantly improved seroconversion, although it is slightly lower in patients with solid cancer compared with healthy individuals.Human vaccines & immunotherapeuticsSeroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.PMC9746490112102310306119Li YWang CZhang XChen YYin JfalseSeroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.Patients with solid cancer have an increased risk of severe coronavirus disease 2019 (COVID-19) and associated mortality than the general population. This meta-analysis aimed to investigate the currently available evidence about the efficacy of COVID-19 vaccines in patients with solid cancer. We included prospective studies comparing the immunogenicity and efficacy of COVID-19 vaccines between patients with solid cancer and healthy individuals. Relative risks of seroconversion after the first and second dose of a COVID-19 vaccine were separately pooled with the use of random effects meta-analysis. Thirty studies with 11,245 subjects met the inclusion criteria. After first vaccine dose, the pooled RR of seroconversion in patients with solid cancer <i>vs</i> healthy individuals was 0.54 (95% CI 0.38-0.78, <i>I</i>^<i>2</i> = 94%). After a second dose, the pooled RR of seroconversion in patients with solid cancer <i>vs</i> healthy controls was 0.87 (0.86-0.88, <i>I</i>^<i>2</i> = 87%). Our review suggests that, compared with healthy individuals, COVID-19 vaccines show favorable immunogenicity and efficacy in patients with solid cancer. A second dose is associated with significantly improved seroconversion, although it is slightly lower in patients with solid cancer compared with healthy individuals.2022-01-01T00:00:00Z2022 Nov2026-06-20T03:18:01.777Z2025-04-04T19:11:16.335ZS-EPMC97464903616197610.1080/21645515.2022.2119763